Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 8/20 | 0.98 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.98 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.98 |
| ▸ | PRKCG | P05129 | 5/20 | 0.98 |
| ▸ | PRKCB | P05771 | 5/20 | 0.98 |
| ▸ | PRKCA | P17252 | 5/20 | 0.98 |
| ▸ | PRKCH | P24723 | 5/20 | 0.98 |
| ▸ | PRKCI | P41743 | 5/20 | 0.98 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.98 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.98 |
| ▸ | PRKACA | P17612 | 4/20 | 0.98 |
| ▸ | PRKACG | P22612 | 4/20 | 0.98 |
| ▸ | PRKACB | P22694 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL4674 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL6269832 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL29381868 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL29362990 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL599053 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL317082 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL30084458 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL29393852 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL6032335 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 | |
| Fasudil SCHEMBL29351490 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1PRKCEPRKCDPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584106-B2 | Method for producing oligodendrocyte-like cells | JSR CORPORATION (JP) | 2026-03-24 | — | — | US | disclosed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| EP-4428230-A1 | CULTURE METHOD, CULTURE PRODUCT, SPHEROID, AND METHOD FOR SCREENING FOR TEST SUBSTANCE | JSR Corporation (JP) | 2024-09-11 | — | — | EP | disclosed |
| US-20240279605-A1 | CULTURE METHOD, CULTURE PRODUCT, SPHEROID, AND METHOD FOR SCREENING FOR TEST SUBSTANCE | JSR CORPORATION (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-4410958-A1 | ORGANOID PRODUCTION METHOD, CULTURE MEDIUM FOR ORGANOID PRODUCTION, ORGANOID, AND TEST SUBSTANCE EVALUATION METHOD | JSR Corporation (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-20240183843-A1 | METHOD FOR EVALUATING EXCRETION OF SUBSTANCE OF INTEREST BY HUMAN HEPATOCYTE-LIKE CELL | JSR CORPORATION (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240174985-A1 | METHOD FOR PRODUCING OVARIAN SOMATIC CELL-LIKE CELLS, AND METHOD FOR INDUCING DIFFERENTIATION OF PRIMATE PLURIPOTENT STEM CELLS INTO OVARIAN SOMATIC CELL-LIKE CELLS | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-118103497-A | Culture method, culture, cell aggregate, and method for screening test substance | JSR株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-117957310-A | Method for producing organoid, culture medium for organoid production, organoid, and method for evaluating test substance | JSR株式会社 | 2024-04-30 | — | — | CN | disclosed |
| US-20240084260-A1 | METHOD FOR CULTURING HUMAN HEPATIC PARENCHYMAL CELL, CULTURED HUMAN HEPATIC PARENCHYMAL CELL, CULTURE MEDIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CULTURE SUPERNATANT OF HUMAN HEPATIC NONPARENCHYMAL CELL | KEIO UNIVERSITY (JP) | 2024-03-14 | — | — | US | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-6190691-B1 | ADMINISTERING FORMULATION COMPRISING TUMOR NERCOSIS FACTOR (TNF) PRODUCTION-INHIBITORY AMOUNT OF A COMPOUND SELECTED FROM LOPERAMIDE AND DIPHENOXYLATE TO MAMMAL | ADOLOR CORPORATION | 2001-02-20 | — | — | US | disclosed |
| EP-0937460-A2 | Use of an antidiarrheal for the manufacture of a medicament for the treatment of inflammatory conditions | Adolor Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0757558-A4 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORP (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0757558-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK2 5/4885ROCK1 4/4885PRKCE 327/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | ROCK2 896/4885ROCK1 1428/4885PRKCE 435/4885 |
| US-12584106-B2 | Method for producing oligodendrocyte-like cells | POU2F2, POU2F1, POU5F1 | ROCK2 233/4885ROCK1 982/4885PRKCE 3223/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ROCK2 677/4885ROCK1 622/4885PRKCE 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.